top of page

Leveraging MPS Data for in-Silico Modeling

With new approach methodologies (NAM) evolving in tandem and at a rapid pace, there is an opportunity to integrate them in ways previously thought impossible. This session aims to initiate discussion on how the diverse and complex datasets derived from CIVM and MPS models may be analyzed using quantitative systems biology (QSP), machine learning, and in silico modeling approaches. Examples will be provided through case studies, and a realistic view of the current gaps as well as future outlooks and opportunities will be discussed.

Date & Time

Thursday, September 21, 2023 at 10:00 AM ET

Duration

90 minutes

Agenda

Welcome and Introduction

David Stresser, AbbVie


PBPK as essential tools for MPS integration in Drug Development

Diane Ramsden, AstraZeneca


Advancing Drug Development with MPS-PBPK Integration

Maarten Huisman, UCB Pharma


Q&A

David Stresser, AbbVie


Quantitative translation of MPS toxicity into Clinical Adverse Effects

Carmen Pin, AstraZeneca


Q&A

Diane Ramsden, AstraZeneca


Session Slides:


IQ MPS PharmTox Training Module 1 Sesssion 4 - Leveraging MPS
.pdf
Download PDF • 8.60MB

Moderators and Presenters

Diane Ramsden

Director, Oncology DMPK

AstraZeneca

<h2 class="font_2"><strong>Diane Ramsden</strong></h2>
<p class="font_8">Director, Oncology DMPK</p>
<p class="font_8">AstraZeneca</p>

Diane Ramsden is a Director of Oncology DMPK leading the ADME and BA team within AstraZeneca’s Boston site. Her team is evaluating MPS and CIVM models as tools for providing mechanistic ADME insights into small and large molecule disposition.

<h2 class="font_2"><strong>Diane Ramsden</strong></h2>
<p class="font_8">Director, Oncology DMPK</p>
<p class="font_8">AstraZeneca</p>

David Stresser, PhD

Research Fellow

AbbVie

David Stresser is a Senior Principal Research Scientist in the DMPK-BA department at AbbVie and leads a team of ADME scientists focusing on investigations of small molecule clearance, plasma protein binding and drug-drug interactions using conventional and complex in vitro models. He is an active participant in various pharma consortia including the IQ Microphysiological Systems Affiliate.

<h2 class="font_2"><strong>Diane Ramsden</strong></h2>
<p class="font_8">Director, Oncology DMPK</p>
<p class="font_8">AstraZeneca</p>

Maarten Huisman

Director, Quantitative Pharmacology and DMPK

UCB Pharma

Maarten Huisman is a seasoned translational scientist with a Ph.D. in Pharmaceutical Sciences from Utrecht University and a MSc in Biology: Molecular and Medical Genetics from the University of Groningen. He currently serves as the DMPK Lead at UCB, focusing on the discovery and development of novel protein degraders, ASO-conjugates, and antibodies.

Before UCB, Maarten held various roles at 3D-PharmXchange, Oystershell Laboratories (Medical Devices), and 2 Bridge CVBA, and contributed significantly at The Janssen Pharmaceutical Companies of Johnson & Johnson. He's adept in strategic planning, project leadership, and embracing new technologies for drug development. His expertise spans several therapeutic areas including oncology, dermatology, immunology, diabetes, and CNS.

Carmen Pin

Senior Director

AstraZeneca

Dr. Carmen Pin is a modeler at AstraZeneca (Cambridge, UK). Prior to joining AstraZeneca, she led the Computational Gastrointestinal Biology Group at the Quadram IB (Norwich, UK). She has co-authored numerous scientific articles and led several substantial scientific research projects.

bottom of page